Oxygen Biotherapeutics Mission & Goals
News & Events
Oxygen Biotherapeutics Inc. Provides an Update on Communication with the FDA Regarding Oxycyte Development Program
Tuesday, March 4, 2014 5:00 am PST
Public Company Information:
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has been notified by the U.S. Food and Drug Administration (the “FDA”) that the agency has completed its review of the September 2013 nonclinical submission and has lifted the clinical hold on Oxycyte®. Lifting of the clinical hold clears the company to proceed with the clinical development program in the US. The FDA communicated this information to the company during a conference call with the FDA on Friday, February 28, 2014. Written confirmation of the FDA’s decision is expected to be received within 30 days. more..
The Mission of Oxygen Biotherapeutics is to develop and market specialty pharmaceutical products that address unmet needs of critical care patients, their health care providers, and the hospitals who treat these patients.